Navigation Links
Dr. Avrum Spira receives award for advancing research on tobacco smoke's effect on lungs
Date:10/28/2013

(Boston) Avrum Spira, MD, MSc, the Alexander Graham Bell professor of medicine and chief of the division of computational biomedicine at Boston University School of Medicine, is the recipient of the Alton Ochsner Award Relating Smoking and Disease. The award will be presented to Spira today at the Opening Session of the Annual Meeting of the American College of Chest Physicians in Chicago.

This award recognizes Spira's seminal research contributions that have enhanced the understanding of the biological response of lung tissue to tobacco smoke, which can cause lung cancer and chronic obstructive lung disease (COPD). Spira has applied innovative approaches to measure gene expression in populations of lung cells damaged by tobacco toxins and was the first to define the reversibility and permanent impact of cigarette smoke on gene activity in the bronchial airway. Spira's lab has leveraged this genomic response in the airway to develop an early detection biomarker that can enable physicians to diagnose lung cancer earlier among smokers at risk for disease. This has important scientific, clinical and therapeutic implications. More recently, his group has extended this genomic approach to develop molecular biomarkers that can guide treatment decisions in COPD and identify novel therapeutic opportunities for this chronic debilitating disease.

Spira, who also is a physician in the pulmonary, critical care and allergy department at Boston Medical Center, is a graduate of Vanier College, Montreal, Canada, the McGill University Faculty of Medicine, also in Montreal, and Boston University (BU). He also is the Director of the Translational Bioinformatics Program within the Clinical Translational Science Institute of BU.

The Award is named in honor of Doctor Alton Ochsner, co-founder of the Ochsner Clinic in New Orleans. In 1939, Ochsner was the first to publish evidence relating cigarette (tobacco) smoking as the primary cause of lung cancer.


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
2. Vitamin D supplementation can decrease risk of respiratory infections in children
3. Gene linked to respiratory distress in babies
4. Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia
5. DNA damage: The dark side of respiration
6. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
7. Pro Ana and Thinspiration Sites Under Attack
8. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
9. Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award
10. UF receives $1 million from Keck Foundation to study mechanisms of inherited disease
11. Gladstone scientist Warner C. Greene receives Washington University School of Medicine Alumni Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... -- AIC announces that it has just released a new white paper authored by Zettar ... high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... 08, 2016 , ... KBioBox llc announced today the launch ... developed a sophisticated “3 click” gene dditing off target analysis program and a ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
Breaking Biology Technology: